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Abstract
Plasmodium falciparum: apical membrane antigen 1 (AMA1) is a candidate malaria vaccine antigen expressed on
merozoites and sporozoites. The polymorphic nature of AMA1 may compromise vaccine induced protection. The humoral
response induced by two dosages (10 and 50 mg) of a single allele AMA1 antigen (FVO) formulated with Alhydrogel,
Montanide ISA 720 or AS02 was investigated in 47 malaria-naı¨ve adult volunteers. Volunteers were vaccinated 3 times at 4
weekly intervals and serum samples obtained four weeks after the third immunization were analysed for (i) Antibody
responses to various allelic variants, (ii) Domain specificity, (iii) Avidity, (iv) IgG subclass levels, by ELISA and (v) functionality
of antibody responses by Growth Inhibition Assay (GIA). About half of the antibodies induced by vaccination cross reacted
with heterologous AMA1 alleles. The choice of adjuvant determined the magnitude of the antibody response, but had only
a marginal influence on specificity, avidity, domain recognition or subclass responses. The highest antibody responses were
observed for AMA1 formulated with AS02. The Growth Inhibition Assay activity of the antibodies was proportional to the
amount of antigen specific IgG and the functional capacity of the antibodies was similar for heterologous AMA1-expressing
laboratory strains.
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Introduction
Malaria is a serious public health problem causing high levels of
morbidity and mortality in malaria-endemic regions [1]. An
effective malaria vaccine will contribute to reducing the burden of
malaria in addition to existing measures like insecticide-treated
bed nets, antimalarials and vector control.
Apical Membrane Antigen 1 (AMA1) is a promising malaria
vaccine candidate (reviewed in [2]), expressed on merozoites and
sporozoites as a type I integral membrane protein [3,4] and is
initially located in the micronemes [3,5]. In Plasmodium falciparum
AMA1 is expressed as an 83 kDa protein and relocates as a
66 kDa protein to the parasite surface following cleavage of the
pro-sequence at the time of invasion [6], where it is subsequently
shed as 44 and 48 kDa forms [6]. The AMA1 ectodomain consists
of an N-terminal pro-sequence and three tightly interacting
domains [7,8]. AMA1 is believed to play an essential role in red
blood cell invasion [9] and may also be implicated in liver cell
invasion by sporozoites [4]. The protective efficacy of AMA1-
based vaccines has been demonstrated in numerous mouse and
simian models (reviewed in [2]).
AMA1 is a polymorphic antigen [10], and this polymorphism is
entirely due to single amino acid substitutions [7]. These
polymorphisms have been found to be restricted to the surface
of AMA1, predominantly mapping to one molecular face [7,8,11].
Studies with the rodent malaria P. chabaudi have shown that
polymorphism in AMA1 can ablate vaccine efficacy [12]. Rabbit
immunisation studies have demonstrated that, although antibodies
raised against one PfAMA1 allele show excellent inhibition of
strains expressing a homologous allele, strains expressing a
heterologous PfAMA1 allele are inhibited to a variable lesser
degree depending on the antigenic differences and their locations
[13–17], suggesting that PfAMA1 polymorphism reduces the
efficacy of PfAMA1 based vaccines. Results from a Phase IIb
vaccine study in Malian children suggests that the specificity of the
AMA1 immune response is crucial in protection [18].
Most of the data addressing the impact of polymorphism have
been generated in laboratory animals and relatively little is known
from human vaccination studies. A phase Ia study with 10 or
50 mg of a single allele vaccine (PfAMA1 FVO-strain, amino acids
25–545) formulated with three adjuvants [19] in malaria-naı¨ve
subjects offers a unique opportunity to perform an in depth
analysis of antibody responses in humans. Total IgG and GIA
responses to the homologous antigen have been reported
previously [19]. The analysis reported here comprises ELISA
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and Growth Inhibition Assay (GIA) titres to the homologous and
heterologous AMA1 antigens, domain specificity, subclass distri-
bution, avidity and the relation between GIA and ELISA titres
after 3 immunisations with PfAMA1 FVO 25–545. In addition, it
also offers the opportunity to investigate the effect of various
adjuvants on the quality and quantity of the humoral immune
response.
Materials and Methods
Participants
Fifty-six malaria-naı¨ve healthy male study participants were
recruited at the Radboud University Nijmegen Medical Centre
as previously reported [19]. The Dutch regulatory authorities
advised to only enrol males, because no reproductive toxicology
data were available for the vaccine formulations. A total of 47
subjects completing all 3 immunisations were included for the
per protocol analysis in the current paper [19]. A total of 8
subjects were withdrawn because of adverse events (1 Rash, 7
Erythema). Of the 7 erythema cases 2 and 4 occurred in the
AS02 10 and 50 mg groups, respectively [19]. One volunteer
was withdrawn because of concomitant hepatitis vaccination
[19]. The characteristics of the subjects at the time of first
vaccination are presented in Table 1. All volunteers provided
written informed consent. The study was approved by the
Institutional Review Board (CMO Regio Arnhem-Nijmegen,
2005/015). The study was conducted in accordance with the
Declaration of Helsinki principles for the conduct of clinical
trials and the International Committee of Harmonization Good
Clinical Practice Guidelines and registered at www.clinicaltrials.
gov (NCT00730782).
Vaccines, Vaccination and Blood Samples
Clinical grade PfAMA1 FVO[25–545] consisting of P.
falciparum FVO-strain AMA1 ectodomain (amino acids 25 to
545) was produced as previously described [20]. The cGMP
(current Good Manufacturing Practice) produced PfAMA1
FVO[25–545] was available in multidose vials containing
120 mg lyophilised AMA1 (44 mg EDTA, 180 mg saccharose
and 120 mg NaHCO3, Lot B) or 62.5 mg lyophilised AMA1
(23 mg EDTA, 25 mg saccharose, 226 mg K2HPO4 and
187 mg NaH2PO4, Lot C). PfAMA1 vaccines of 0.5 mL were
prepared at two dosages (10 and 50 mg) with three different
adjuvants (Alhydrogel, Montanide ISA 720 or AS02) as
previously described [19]. Alhydrogel and Montanide ISA 720
vaccines were prepared with lot B PfAMA1 and AS02 vaccines
were prepared with lot C PfAMA1; the excipientation of lot C
was specifically optimised for compatibility with AS02. Formu-
lated vaccines were kept at 4uC for a maximum of six hours
until administration. Vaccine formulations were tested for
stability as previously described [20] and all fulfilled the pre-
set specifications. Immunisations were given intramuscularly in
the deltoid region of alternate arms at days 0, 28 and 56. Blood
was collected in VacutainerTM CPT tubes (Becton and
Dickinson), plasma collected after centrifugation and stored at
220uC.
Quantification ELISA for Total IgG and IgG Subclasses
Enzyme-linked immunosorbent assay (ELISA) was performed
in duplicate on plasma samples in 96 well flat-bottomed
microtitre plates (Greiner, Alphen a/d Rijn, The Netherlands),
coated with 1 mg/mL purified AMA1 antigens according to
published methods [10]. The sequences of the four Pichia pastoris-
expressed AMA1 proteins used for ELISA are shown in Figure 1,
potential N-glycosylation sites were removed as previously
described [10,15] and proteins were produced as previously
described [20]. The P. pastoris-expressed AMA1 from 3D7, HB3
and CAMP used in the ELISA’s differ by 26 (2, 17, 5 and 2 for
prodomain and domains I, II and III, respectively), 20 (2, 11, 4,
3 for prodomain and domains I, II and III, respectively) and 17
(3, 9, 3, 2 for prodomain and domains I, II and III, respectively)
amino acid positions in the ectodomains (aa 25–545) (Figure 1).
The secondary antibody for total IgG was goat anti-human IgG
conjugated to alkaline phosphatase (Pierce, Rockford, IL). The
reagents used for the total IgG ELISA to the AMA1 alleles were
the same except for the coating antigens and the ELISA’s were
all performed in one run and the coating antigens were of
comparable quality and purity. As all ELISA’s were done in one
run with comparable reagents it is assumed that an OD of 1 over
blank represents equal amounts of antibodies. For the IgG
subclasses the mouse monoclonals conjugated to horseradish
peroxidase were used: M1328 (clone MH161-1), M1329 (Clone
MH162-1), M1330 (Clone MH163-1) and M1331 (Clone
MH164-1) for IgG1, IgG2, IgG3 and IgG4, respectively
(Sanquin, Amsterdam, The Netherlands). These monoclonal
antibodies are confirmed to be specific for the designated
subclass and show no cross reactivity with other IgG subclasses
at the recommended working dilutions. A serum pool from .50
exposed African adults was included on each plate and antibody
levels in the unknowns were calculated using a four-parameter
fit. Titres are expressed as arbitrary units, where 1 AU yields an
OD of 1 over background. Thus the amount of AU of a sample
is the reciprocal dilution at which an OD of 1 over background
will be achieved. One arbitrary antibody unit for total IgG
corresponds to approximately 15 ng mL21 of antigen specific
IgG.
Competition ELISA
Competition ELISA was performed as previously described [16].
Dilutions that resulted in 2 AU (yielding an OD of about 1.5 over
blank) were calculated for each plasma sample and used in the
subsequent antigen competition assay. The assay involved co-
incubation of different allelic forms of PfAMA1, or PfAMA1-FVO
domains with test plasma in plates coated with PfAMA1 FVO allele,
such that competition occurs between the added (competitor)
antigens and the coated antigen for binding to test IgG’s. For the
AMA1 allelic forms the competitor/soluble antigens were titrated 3-
fold over 7 wells from 100 to 0.137 mg mL21 with PfAMA1 from the
FVO, 3D7, HB3 or CAMP alleles (Figure 1). For the PfAMA1-FVO
domains competition ELISA, plates were coated with FVO AMA1
amino acids 97 through 545 (Domains I, II and III) a fixed
concentration of 30 mg mL21 of various FVO AMA1 domain
Table 1. Characteristics of the subjects at the time of first
vaccination (per protocol). Age is presented as mean 6
standard deviation.
Adjuvant Dose N Age Minimum Maximum
Alhydrogel 10 9 23.362.9 21.1 29.5
Alhydrogel 50 10 23.262.1 19.4 26.9
ISA720 10 8 23.165.2 18.5 33.7
ISA720 50 9 23.263.6 19.7 31.1
AS02 10 7 24.568.3 20.0 42.8
AS02 50 4 24.364.8 20.5 31.3
doi:10.1371/journal.pone.0038898.t001
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constructs were used as competitors (pro-DI-II-III aa 25–545, DI-II
aa 97–442, DII-III aa 303–545 and DII aa 303–442). The
appropriately diluted plasma was then added and after incubation
for 2 h, plates were developed as described above. Values are
presented as the fraction remaining relative to the initial amount.
Avidity ELISA
The avidities of the antibodies were determined by sodium
isothiocyanate (NaSCN) elution ELISA as previously described
[16]. Briefly, microtitre plates were coated with AMA1 variant
proteins (Figure 1) as described above, and after blocking,
incubated with a pre-determined titre (1 AU) of sera for 1 h.
Plates were then washed and incubated with an increasing
concentration of NaSCN (ranging from 0 to 3.0 M in 0.25 M
steps) in duplicate wells for 15 min. Plates were washed and
developed with goat anti-human IgG alkaline phosphatase
conjugate and substrate as previously described [16]. The avidity
index is expressed as the concentration of NaSCN required for
50% dissociation of bound antibodies (relative to duplicate wells
without NaSCN).
Growth Inhibition Assay (GIA)
Antibodies used for growth inhibition assays (GIA) were
purified from CPT plasma on protein A columns (Immunopure
Plus Pierce, St Louis, MO, USA), exchanged into RPMI 1640
using Amicon Ultra-15 concentrators (30 kDa cutoff, Millipore,
Ireland), filter-sterilised and stored at 220uC until use. IgG
concentrations were determined using a Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Wilmington, DE,
USA). P. falciparum strains FCR3, 3D7 and HB3 were cultured
in vitro using standard culture techniques in an atmosphere of
5% CO2, 5% O2 and 90% N2. FCR3 AMA1 (accession no.
M34553) differs by one amino acid in the pro-sequence (D36G)
from FVO AMA1 (accession no. AJ277646) and is considered
the homologous AMA1 antigen for the FVO allele. The
ectodomain (amino acids 25–545) of 3D7 (accession no.
U65407) differs by 26 amino acids (2, 17, 5 and 2 for
prodomain and domains I, II and III, respectively) from FVO
and the ectodomain of HB3 (accession no. U33277) differs by
21 amino acids (2, 12, 4 and 3 for prodomain and domains I,
II and III, respectively) from FVO.
Figure 1. Alignment of AMA1 protein sequences amino acids 25 through 545 used for ELISA measurements. Amino acid positions are
indicated above the sequences for each decimal and every fifth position is indicated by an asterisk (*). Each line represents an AMA1 allele, for FVO,
3D7, HB3 and CAMP, respectively. D glyc indicates that it concerns sequences that have been mutagenised to avoid potential N-glycosylation sites.
Potential N-glycosylation sited were changed (six for FVO, 3D7 and CAMP and five for HB3) to avoid unwanted N-glycosylation: N 162 K (For FVO, 3D7
and CAMP. HB3 AMA1 has K at position 162). T 288 V, S 273 D, N 422 D, S 423 K and N 499 Q.
doi:10.1371/journal.pone.0038898.g001
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The GIA was performed as previously described [14]. Briefly,
the effect of purified IgG antibodies on in vitro parasite growth
was evaluated at two IgG concentrations (5 and 10 mg/mL,
respectively) and each participants pre-immune IgG was used as
negative control. A IgG concentration of 10 mg mL21
approximates the amount of IgG (9.5 to 11.5 mg mL21) found
in undiluted human plasma [21]. Samples were run in triplicate
using 96 well flat-bottomed plates with alanine-synchronized
cultures of P. falciparum schizonts at an initial parasitaemia of
0.2–0.4%, a haematocrit of 2.0% and a final volume of 100 mL.
After 40 to 42 hours, cultures were resuspended, and 50 mL was
transferred into 200 mL ice-cold PBS. The cultures were then
centrifuged, the supernatant removed and the plates were
frozen. Parasite growth was assessed by measuring parasite
lactate dehydrogenase levels with the lactate diaphorase APAD
substrate system, and plates were read at 655 nm after 30 min
incubation in the dark. Parasite growth inhibition was expressed
as: 100 6 (1– (OD655 Day84– OD655 RBC)/(OD655 Day0–
OD655 RBC)), Where: OD655Day84 is the OD655 for IgG
purified from day 84 plasma, OD655Day0 is the OD655 for IgG
purified from day 0 plasma and OD655RBC is the average
OD655 of RBC control wells. The data are presented as the
arithmetic mean % inhibition from each sample triplicate.
Statistics
Antibody titres (IgG and IgG subclasses) were log-transformed
to obtain normality and are presented as geometric means with
95% confidence intervals. GIA titres, IgG avidity and levels of
depletion were approximately normally distributed and are
therefore presented as arithmetic means with 95% confidence
intervals. The statistical significance of between group differences
was initially evaluated using one way (comparing the 6 adjuvant-
dose groups directly) Analysis of Variance (ANOVA). Significant
between group differences were further evaluated by Tukey’s
Honest Significant Difference post-hoc test which applies a
correction on the p-value for multiple comparisons and provides
estimates with 95% confidence intervals (95% CI) for the between
group comparisons.
The results from the competition ELISA were analysed using
non-linear mixed effects models (NLME). Where the fraction of
antibody remaining bound at increasing competitor concentration
was modeled separately for each subject by the following formula
describing a sigmoid: Fraction remaining = 1/[1+ Exp((Ln IC50–
Ln IgG ) * Slope) ]. As Slope is difficult to interpret, it is expressed
as the fold-increase in soluble antigen concentration required to
change the fraction remaining bound from 90 to 50% or from 50
to 10%. This fold-increase can be calculated by the following
formula e(2.197/Slope).
NLME models with and with and without treatment effects
were assessed and the model with the lowest Aikake Information
Criterion (AIC) were accepted as best fitting model. The IC50 and
fold increase in competitor required to change the fraction bound
from 90 to 50% were calculated from the regression results.
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Figure 2. IgG levels to the vaccine allele and three variant AMA1 alleles in plasma obtained on day 84. IgG antibody levels to the
vaccine antigen (FVO) and 3 heterologous AMA1 alleles (3D7, HB3 and CAMP). Values for each subject within a treatment group are indicated by a
specific symbol (same symbol within each treatment group is same subject throughout graphs 2, 4, 5, 6 and 7), boxes indicate median and quartile
ranges. Treatment groups are indicated by Adjuvant name and AMA1 dose, respectively.
doi:10.1371/journal.pone.0038898.g002
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The relation between GIA and IgG titres was investigated by
non linear least squares regression using the following formula:
GIA = 100 * 1/[1+ Exp((Ln IC50– Ln IgG ) * Slope) ], where IgG
is the antibody titre, IC50 represents the IgG concentration
yielding 50% inhibition and slope is a parameter indicating the
steepness of the curve, with steeper curves at higher (absolute)
values. Comparisons of IC50 and slope values for the various GIA
strains were done by incorporating dummy variables for both
parameters for both strains in the non linear least squares
regression model.
Results
IgG Responses to AMA1 Alleles
Before vaccination all 47 available plasma samples were negative
for AMA1 IgG antibodies (data not shown) [19]. All available plasma
samples obtained 4 weeks after the third vaccination (Day 84) were
titrated in a single laboratory run on 4 different AMA1 variants; IgG
antibody titres are depicted in Figure 2. The results obtained for the
IgG titres against FVO AMA1 in the 47 day 84 samples are in
agreement with those previously reported (Spearman’s Rho = 0.943,
p,0.0001) [19]. IgG antibody levels were lowest in the Alhydrogel
groups (10 and 50 mg) and in the Montanide ISA 720 10 mg group as
compared to the Montanide ISA 720 50 mg and both AS02 groups,
this trend was consistently observed for all AMA1 variants under
investigation (Figure 2). The IgG antibody levels to the heterologous
AMA1 (3D7, HB3 and CAMP) variants, were approximately 50%
lower as compared to the homologous FVO AMA1 (Figure 2). IgG
antibody levels to all AMA1 variants under investigation were 4 to 5
fold higher in the Montanide ISA 720 50 mg and AS02 10 mg groups
as compared to the Alhydrogel 10 mg group (Figure 2, all p,0.02).
The specificity of the IgG responses in day 84 samples was further
characterised using competition ELISA, where increasing amounts
of competitor antigen were co-incubated with a fixed amount of
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Figure 3. Competition ELISA using four different competitor antigens on FVO coated plates in plasma obtained on day 84.
Concentration of competitor antigen is depicted on the x-axis (mg mL21) and the fraction remaining bound (mean from all individuals in a treatment
group) to the ELISA plate is depicted on the y-axis (%). Light Blue = FVO AMA1 (homologous), Orange = HB3 AMA1, Green = CAMP AMA1 and Dark
Blue = 3D7 AMA1. Treatment groups are indicated by Adjuvant name and AMA1 dose, respectively.
doi:10.1371/journal.pone.0038898.g003
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antibodies. Figure 3 shows that the addition of increasing amounts of
antigen reduces the amount of bound antibody for all competitor
antigens, with the most pronounced reduction observed for the
homologous antigen; the heterologous antigens also reduced the
amount of IgG remaining bound, but less efficiently as compared to
the homologous antigen. The depletion curves per competitor
antigen were similar, as judged by IC50 and slope parameters, for the
adjuvant and dose groups, suggesting neither adjuvant nor dose
markedly influenced antibody specificities (Figure 3). The amount of
competitor antigen required to remove 50% of antibodies (IC50) was
lowest forFVOat0.23 mgmL21 (95%CI0.21to0.26),1.47 mgmL21
(95% CI 1.08 to 2.02) for HB3, 4.39 mg mL21 (95% CI 2.93 to 6.57)
for CAMP and 20.15 mg mL21 (95% CI 14.17 to 28.65) for 3D7
(Figure3).Theincrease incompetitorantigenconcentrationrequired
to reduce the remaining amount of bound antibodies from 50 to 10%
was 38-fold (95% CI 34 to 43) for FVO AMA1. The slopes for the
heterologous AMA1proteins indicated that a much larger increase in
competitor concentration was required to reduce the amount of
bound antibodies from 50 to 10%: 1015-fold (95% CI 702 to 1535),
1328-fold (95%CI920to2001)and910-fold (95%CI471to2058) for
HB3, CAMP and 3D7 AMA1, respectively (Figure 3).
IgG Responses to AMA1 Domains
The domain specificity of the antibody response at day 84 was
investigated using competition ELISA’s, where fixed amounts
(30 mg) of PfAMA1-FVO domains were added. Figure 4 shows
that 7.2% (95% CI 3.3 to 11.2) of the IgG remained bound after
the addition of 30 mg of the full length antigen (p-DI-II-III),
indicating over 90% depletion and suggesting that the 30 mg mL21
is close to saturation. The fraction of IgG remaining after the
addition of the full length antigen did not differ for the groups
(p = 0.36). After addition of domains I-II approximately 19.0%
(95% CI 17.6 to 20.5) of the IgG remained bound, indicating more
than 80% depletion. The addition of domains I-II resulted in
significant between group differences in the fraction remaining
bound (p = 0.0009, ANOVA). More IgG remained bound In the
Montanide ISA 720 10 mg group when compared to the
Alhydrogel 50 mg and AS02 50 mg groups, (7.8% (95% CI 2.0
to 13.6, p = 0.0030, Tukey HSD) and 10.9 (95% CI 3.4 to 18.4.
p = 0.0011, Tukey HSD). A similar trend, albeit not significant,
was observed when comparing the Montanide ISA 720 50 mg
group with the AS02 50 mg group (7.2% difference, 95% CI
20.17 to 14.5, p = 0.059, Tukey HSD). This suggests that
Montanide ISA 720 induces more antibodies directed against
domain III. No significant differences were observed between the
treatment groups following depletion with domains II-III or
domain II only (p values 0.16 and 0.051, respectively, ANOVA).
The average amount of IgG remaining bound was 21.1% (95% CI
19.2 to 23.0) and 61.5% (95% CI 57.1 to 66.0) for domains II-III
and domain II, respectively.
Antibody Avidity
Antibody avidity in individual plasma samples collected on day
84 was quantified using a sodium thiocyanate (NaSCN) elution
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Figure 4. Competition ELISA using AMA1 domain constructs in plasma obtained on day 84. The fraction of antibodies remaining bound
after competition with 30 mg of the indicated competitor are depicted on the y-axis, boxes indicate median and quartile ranges. P-DI-II-III = FVO
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ELISA and expressed as the concentration of NaSCN required to
reduce the amount of bound antibody by 50%, shown in Figure 5.
Adjuvant or antigen dose did not significantly influence the
average avidity to the AMA1 variants under investigation
(p = 0.169, p = 0.725, p = 0.864 and p = 0.609 for FVO, 3D7,
HB3 and CAMP, respectively). The mean concentration of
thiocyanate required for 50% elution was 0.694 M (95% CI
0.660 to 0.725) for the homologous FVO AMA1. For the
heterologous antigens these were: 0.609 M (95% CI 0.542 to
0.676), 0.711 M (95% CI 0.602 to 0.820) and 0.929 M (95% CI
0.775 to 1.083) for 3D7, HB3 and CAMP AMA1, respectively.
Antibody avidity to the 3D7 AMA1 was significantly lower than to
the homologous FVO AMA1 (p = 0.006, paired t-test). By
contrast, antibody avidity to the CAMP AMA1 was significantly
higher than to the homologous FVO AMA1 (p = 0.002, paired t-
test). Antibody avidities to the HB3 allele were similar to those
observed for the FVO allele (p = 0.742, paired t-test).
Subclass Distribution
IgG subclass levels to the homologous FVO AMA1 allele
determined in plasma samples taken on days 0 and 84. Pre-
vaccination subclass levels were low and no significant differences
were observed between the treatment groups. Following vaccina-
tion IgG1, IgG2, IgG3 and IgG4 levels all increased significantly
(p,0.001, Wilcoxon signed rank test). Day 84 subclass levels are
shown in Figure 6. The ranking of IgG subclasses in descending
titre order was IgG1. IgG3 < IgG4. IgG2. IgG1 and IgG3
antibody levels showed a similar pattern as to what was observed
for total IgG, with lowest titers in the Alhydrogel groups (10 and
50 mg) and in the Montanide ISA 720 10 mg group as compared to
the Montanide ISA 720 50 mg and both AS02 groups (Figure 6).
Interestingly, titre differences between the treatment arms were
slightly higher for IgG3 as compared to IgG1 (Figure 6).
GIA
The results of the Growth Inhibition Assay (GIA) for three
laboratory strains obtained with IgG fractions purified from plasma
samples collected at day 84 are shown in Figure 7. GIA titres
determined on the FCR3 laboratory strain expressing an AMA1
similar to the vaccine antigen were below 20% in most (22/27)
subjects in the Alhydrogel (10 and 50 mg) and Montanide ISA 720
10 mggroups;only5outof27subjectshadGIAtitreshigher than20%
at 10 mg mL21 total IgG. By contrast, 14 out of 20 subjects in the
MontanideISA720 (50 mg)andAS02 (10and50 mg)groupshadGIA
titres exceeding 20% at 10 mg mL21 total IgG (Figure 7). Average
GIAresponsesweresignificantlyhigher (38.7%-points,95%CI4.7to
72.6%,p = 0.018,TukeyHSD)intheAS0210 mggroupascompared
to the Alhydrogel 10 mg group. The GIA values at 10 mg mL21 total
IgG in Montanide ISA 720 and AS02 50 mg groups were also higher
than the Alhydrogel 10 mg group, but this failed to achieve statistical
significance (p = 0.17 and 0.20, respectively, Tukey HSD, Figure 7).
The GIA titres determined on the FCR3 strain at 5 mg mL21 total
IgG were lower and showed a ranking similar to what was observed at
10 mg mL21, but none of the between group comparisons reached
statistical significance (p = 0.070, ANOVA, Figure 7).
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GIA titres determined on the 3D7 laboratory strain at 10 mg
mL21 IgG were lower than those to the FCR3 strain at the same
total IgG concentration and no significant differences were
observed between the treatment groups (p = 0.095, ANOVA).
Interestingly, GIA titres on the 3D7 strain at 10 mg mL21 were
similar to GIA titres to the homologous FCR3 strain at 5 mg
mL21 total IgG (Figure 7). GIA titres on the 3D7 laboratory strain
at 5 mg mL21 IgG were low; only 2 out of 47 subjects had GIA
titres higher than 20% (Figure 7).
GIA titres determined on the HB3 laboratory strain at 10 mg
mL21 IgG were lower than to the FCR3 strain and similar to the
titres observed for the 3D7 strain. Significant treatment group
differences were observed (p = 0.004, ANOVA). GIA titres in the
AS02 10 mg group were significantly higher than in the Alhydrogel
10 mg group (24.6%-points, 95% CI 3.4 to 45.8%, p = 0.014,
Tukey HSD) and GIA titres in the AS02 10 mg group tended to be
higher as compared to the Alhydrogel 50 mg group (20.5%-points,
95% CI 20.2 to 41.3%, p = 0.053, Tukey HSD) and the
Montanide ISA 720 10 mg group (21.2%-points, 95% CI 20.6
to 42.9%, p = 0.061, Tukey HSD). GIA titres on the HB3
laboratory strain at 5 mg mL21 total IgG were low, with only 4
out of 47 subjects having GIA titres of over 20%. GIA titres on the
HB3 laboratory strain at 5 mg mL21 IgG in the AS02 10 mg
group tended to be higher, similar to what was observed at 10 mg
mL21 total IgG, but this failed to reach statistical significance
(p = 0.091, ANOVA).
Relation between IgG and GIA Titres
The relation between AMA1 variant-specific IgG and GIA was
investigated by modeling sigmoid curves using non-linear least
squares regression. The data are graphically presented in Figure 8.
The R2 values were 0.830 (95% CI 0.714 to 0.902, p,0.0001) for
FCR3, 0.632 (95% CI 0.433 to 0.776, p,0.0001) for 3D7 and
0.631 (95% CI 0.431 to 0.775, p,0.0001) for HB3. The IC50
values, i.e. the amount of AMA1 specific IgG in plasma required
for 50% inhibition were estimated at 31.3 kAU mL21 (95% CI
27.7 to 35.4) for FCR3, 39.8 kAU mL21 (95% CI 30.8 to 51.3) for
3D7 and 38.9 kAU mL21 (95% CI 28.9 to 52.5) for HB3
(Figure 8), which was not significantly different from the value for
the FCR3 strain (p = 0.08 and 0.20, respectively). The fold-
increase in AMA1 variant specific IgG required to raise the GIA
titre from 10 to 50% or from 50 to 90% was 3.5-fold (95% CI 2.7
to 5.0) for FCR3, 2.9-fold (95% CI 2.2 to 5.7) for 3D7 and 4.5-fold
(95% CI 3.1 to 9.5) for HB3, the values for the 3D7 and HB3
strains were not significantly different from the value for the FCR3
strain (p = 0.50 and p = 0.33, respectively).
The correlation between antibody avidity and GIA was
investigated using (non-parametric) rank correlation tests (Spear-
man). No significant correlations were observed between antibody
avidity to an AMA1 variant and GIA values for a strain expressing
a similar AMA1. This may be due to the fact that the variation in
avidity values was relatively limited and that the GIA activity is
mainly determined by the levels of IgG.
Correlations between IgG subclass levels and GIA to FCR3
were investigated using (non-parametric) rank correlation tests
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(Spearman’s Rho). Correlations between FCR3 GIA and subclass
levels were: rho = 0.727, p,0.0001 for IgG1, Rho = 0.027,
p = 0.855 for IgG2, Rho = 0.665, p =,0.0001 for IgG3 and Rho
= 0.480, p =,0.001 for IgG4.
Discussion
The main finding of this study is that AMA1 antibody responses
induced by vaccination of malaria-naı¨ve human volunteers with a
single AMA1 variant are biased towards the vaccine allele. This is
in agreement with previously published results from a similar
human Phase I vaccine trial [22] and observations in rabbits
[14,16]. Approximately half of the IgG induced by vaccination of
human volunteers reacts in ELISA with heterologous AMA1
variants, similar to what has been observed in rabbits [14,16]. The
functionality of the antibody response (GIA titre) to heterologous
AMA1 expressing strains reflects differences in the quantity of
IgG; suggesting that, although absolute antibody levels to
heterologous AMA1 variants are lower, these antibodies are, on
per mass basis, equally capable of inhibiting parasite growth.
The data presented here also demonstrate that both adjuvant
and dose can have a profound impact on antibody levels, while
other aspects of the antibody response like avidity, domain
recognition, breadth and subclass distribution, are much less
influenced by adjuvant or dose. This is, with exception of the
subclass distribution, in agreement with what has been observed in
rabbit studies [23].
The data presented here show that the widely used adjuvant
Alhydrogel yields relatively low antibody levels, and increasing the
antigen dose from 10 to 50 mg only marginally improved antibody
responses. The data confirm that Alhydrogel is not potent enough
to induce high levels of functional antibodies in malaria naı¨ve
subjects, as was previously reported [24,25]. The low potency of
Alhydrogel at inducing a functional response is even more
pronounced when the functionality of the antibody response is
evaluated on strains expressing heterologous AMA1 alleles.
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Therefore adjuvants more potent than Alhydrogel are definitively
required for the induction of functional antibody responses to
AMA1 variants not included in a vaccine.
Recently, vaccination induced efficacy against the AMA1
vaccine allele formulated with AS02 in a Phase IIb study was
estimated at 64%, whereas overall vaccine efficacy was estimated
at 17%, indicating the importance of covering AMA1 variants
[18]. Thus, the challenge for an AMA1-based vaccine appears to
be with covering AMA1 polymorphism. Theoretically, two options
would be available: i) The induction of a broad antibody response
and ii) The maximisation of heterologous antibody responses by
using potent adjuvants or prime boost strategies combined with a
potent adjuvant, such that the response induced with a single
variant would be high enough to also be sufficiently functional
against heterologous strains. As the latter may not be possible with
adjuvants currently available, a more practical approach would be
the combination of the induction of the broadest response possible
with the highest response possible.
The breadth of the antibody response can be improved by
vaccination with a mixture of several AMA1 variants, either
naturally occurring [14,16,23,26], or artificial ones [10,26]. Three
artificial diversity covering (DiCo) AMA1 sequences [10] have
recently been produced under cGMP and will enter clinical testing
in the near future.
The magnitude of the antibody response can be improved by
the use of potent adjuvants, as shown here. A novel proprietary
adjuvant, CoVaccine HTTM, has yielded promising results in
rhesus macaques and rabbits [23,27]. Moreover, P. knowlesi AMA1
formulated with CoVaccine HTTM has induced protection against
blood-stage challenge with P. knowlesi in the rhesus macaque model
and the degree of protection was correlated with GIA titre [28]. It
would therefore be interesting to combine DiCo AMA1 with
CoVaccine HTTM in a Phase I trial.
Antibody avidity was determined with a sodium thiocyanate
elution ELISA and average antibody avidities ranged between 0.6
and 0.9 M for the various antigens. These values are lower than
what was previously observed in rabbits (0.9 to 1.4 M) [16]. Of
note is that the average avidity to the heterologous CAMP AMA1
was higher than the homologous antigen. This could possibly be
explained by the fact that half of FVO AMA1-specific antibodies
bound to CAMP AMA1 and that this fraction may bind with
higher avidity. Conversely, avidities to the heterologous 3D7
AMA1 were lower than the homologous avidities. This may
represent antigenic relatedness of the respective AMA1 molecules,
with CAMP being more close to FVO AMA1 and 3D7 more
distant.
The antibody response to AMA1 appears to be mainly directed
against domains I and II, as competition with a construct
comprising these domains removes about 80% of antibodies
bound. Competition with a domain II-III construct removes a
similar amount of antibodies as the I-II construct, suggesting that
the majority of the response would be directed against domain II.
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This is, however, not supported by the depletion obtained by a
domain II construct. Of note here is that only constructs including
domains I-II induce functionally active antibodies in rabbits
[29,30], suggesting conformational authenticity. The Domain II-
III and the domain II constructs both failed to elicit functionally
active antibodies in rabbits [29,30]. The results obtained here
warrant the statement that the majority of the antibody response
to AMA1 is directed against domains I and II and a further
subdivision for these two domains is not possible with the data
hitherto obtained. The importance of domains I and II in the
antibody response is in agreement with what has been found in
rabbits [29,30].
The subclass distribution found in vaccinated malaria naive
volunteers was similar to what was observed in exposed children
[31,32] and reflects the expected subclass distribution for a protein
antigen [33]. Antigen dose or adjuvant only marginally influenced
the subclass distribution.
In conclusion, vaccination with a single allele AMA1 vaccine
induces a humoral immune response that is biased towards the
vaccine allele. The magnitude of the response can be enhanced by
a potent adjuvant, in contrast other parameters of the humoral
response like breadth, avidity and subclass distribution appear
much less influenced by the adjuvant. Future vaccine development
should focus on improving both breadth and magnitude of
antibody responses to AMA1.
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